Firefly Neuroscience, Inc. (AIFF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 12, 2026, details a material definitive agreement entered into by Firefly Neuroscience, Inc. (the "Company"). The Company, a Delaware corporation listed on the Nasdaq Capital Market under the symbol AIFF, executed a securities purchase agreement to raise capital through a private placement.
Key Financial Metrics and Transaction Details
The filing reports the following specific financial terms regarding the capital raise:
- Initial Investment: $2,250,000 raised at the Initial Closing on March 12, 2026.
- Units Issued (Initial): 1,500,000 Units.
- Purchase Price: $1.50 per Unit.
- Maximum Potential Investment: Up to $18,000,000 in Additional Investments (subject to investor election) within 30 days of the Initial Closing.
- Maximum Units Available: Up to 13,500,000 Units total under the agreement.
Unit Composition: Each Unit consists of:
- One share of Common Stock or a Pre-Funded Warrant (exercise price $0.0001) to avoid beneficial ownership limits (4.99% or 9.99%).
- One "150% Warrant" to purchase one share at $1.88 per share (5-year term).
- One "200% Warrant" to purchase one share at $2.50 per share (5-year term).
Note: The filing does not provide current revenue, profit, cash flow, or debt figures. It focuses exclusively on the terms of this specific financing transaction.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement and a Lock-Up Agreement:
- Registration Rights: The Company agreed to file a registration statement (Form S-1) for the resale of shares and warrant shares by April 15, 2026, with an effectiveness target of 45 to 90 days post-filing.
- Lock-Up Period: Investors are restricted from transferring securities for six months (ending September 12, 2026).
- Leak-Out Period: Following the lock-up, a six-month graduated release schedule applies (ending March 12, 2027), releasing 1/6th of the securities monthly.
- Compliance: The offering was structured to comply with Nasdaq Listing Rule 5635(d) without requiring stockholder approval.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The filing does not contain forward-looking guidance regarding product development, clinical trials, or future financial performance beyond the capital raise mechanics.
Risks and Contingencies:
- Dilution: The issuance of up to 13,500,000 units, including warrants with exercise prices below and above the current purchase price, may result in significant dilution to existing shareholders.
- Beneficial Ownership Limits: Warrant exercises are capped to prevent investors from exceeding 4.99% or 9.99% beneficial ownership, which may limit the immediate liquidity of the warrants.
- Private Placement Restrictions: Securities are sold under Rule 506(b) exemptions and cannot be resold in the U.S. without registration or an applicable exemption.
Key Facts for Investor Verification
- Verify the total number of shares outstanding post-issuance to calculate the exact dilution impact of the 1,500,000 initial units and potential additional units.
- Confirm the status of the Form S-1 registration statement filing by the April 15, 2026 deadline.
- Monitor whether investors exercise their option to purchase the Additional Investment of up to $18,000,000 within the 30-day window.
- Review the beneficial ownership thresholds (4.99% vs. 9.99%) applicable to specific investors to understand the mix of Common Stock vs. Pre-Funded Warrants issued.